Condensed consolidated statements of cash flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Operating activities
Net loss	$ (61,341)	$ (26,698)
Non-cash items:
Stock-based compensation (Note 6(c))	7,017	3,861
Acquired in-process research & development (Note 3)	47,716
Unrealized foreign exchange loss and others	276	628
Changes in operating assets and liabilities:
Receivable, prepayments and deposits	(453)	720
Accounts payable and other liabilities	(3,973)	(313)
Cash used in operating activities	(10,758)	(21,802)
Investing activities
Acquisition of Neoleukin Therapeutics, Inc., net of cash acquired	191
Proceeds from maturity of investments		56,000
Purchase of property and equipment	(97)	(49)
Cash provided by investing activities	94	55,951
Financing activities
Proceeds from exercise of stock options	40	602
Payment on finance lease obligations	(7)	(30)
Cash provided by financing activities	33	572
Effect of exchange rate changes on cash and cash equivalents	9	(22)
Net change in cash and cash equivalents during the period	(10,622)	34,699
Cash and cash equivalents, beginning of period	76,928	52,032
Cash and cash equivalents, end of period	66,306	86,731
Supplemental disclosure of cash flow information:
Interest received	$ 1,279	$ 1,210